All results
12 results for risk and resilience during covid 19
-
TN-31 JAKPOT T1D
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…
- Ages
- 12 Years - 35 Years
- Sexes
- All
-
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…
- Ages
- 12 Years - 99 Years
- Sexes
- All